Company intelligence / Profile preview
CAGE Bio
San Carlos, California, United Statescagebio.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
The lead program, CGB‑500 (topical 1% Tofacitinib in an ionic liquid formulation), achieved positive topline results in a randomized Phase 2 trial for atopic dermatitis. The study met all primary and secondary endpoints with significant improvements in EASI scores and pruritus reduction compared to vehicle. No serious adverse events or local irritation were reported. The company’s technology enables localized delivery of potent drugs with reduced systemic exposure.
- Therapeutic areas
- Dermatology
- Modalities
- Small moleculesproteinsnucleic acids (enabled by proprietary ionic liquid technology)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on CAGE Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAGE Bio.